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Introduction {#sec005}
============

In recent years, the peripheral blood neutrophil--lymphocyte ratio (NLR) and the platelet--lymphocyte ratio (PLR) have been proposed as indicators for evaluating systemic inflammatory responses in cancer-bearing patients and have shown utility as predictive markers for prognosis \[[@pone.0153459.ref001]--[@pone.0153459.ref007]\]. Neoadjuvant chemotherapy (NAC) increases the rate of breast-conserving surgery and reduces the risk of postoperative recurrence in patients with resectable breast cancer \[[@pone.0153459.ref008]--[@pone.0153459.ref011]\]. The main purpose of NAC is its use in building a treatment strategy based on confirmed therapeutic effects and their outcomes through reducing tumor size and improving breast-conservation rates \[[@pone.0153459.ref008], [@pone.0153459.ref012], [@pone.0153459.ref013]\]. To date, we have reported on the usefulness of NLR as a predictor of the effect of NAC in triple-negative breast cancer \[[@pone.0153459.ref006], [@pone.0153459.ref007]\].

Meanwhile, the PLR in preoperative peripheral blood reportedly represents an independent prognostic factor in breast cancer \[[@pone.0153459.ref006], [@pone.0153459.ref007]\]. A high PLR in many types of cancer, including gastric \[[@pone.0153459.ref014]\], colorectal \[[@pone.0153459.ref015]--[@pone.0153459.ref017]\], pancreatic \[[@pone.0153459.ref018]\] and ovarian \[[@pone.0153459.ref019], [@pone.0153459.ref020]\], is said to indicate a poor prognosis. Platelets are cells containing the largest quantity of growth factors, such as platelet-derived growth factor (PDGF) \[[@pone.0153459.ref021]--[@pone.0153459.ref025]\], transforming growth factor (TGF)-β \[[@pone.0153459.ref026], [@pone.0153459.ref027]\] and platelet-derived endothelial cell growth factor (PD-ECGF) \[[@pone.0153459.ref028]--[@pone.0153459.ref030]\]. These platelet-derived growth factors are often produced in large quantities by cancer cells and contribute to cancer growth and histology \[[@pone.0153459.ref025], [@pone.0153459.ref026]\]. Lymphocytes are known to be responsible for the immune response against tumors, suggesting that PLR may be related to prognosis and chemotherapy sensitivity. While some reports suggest a correlation between PLR and prognosis \[[@pone.0153459.ref006], [@pone.0153459.ref007], [@pone.0153459.ref015], [@pone.0153459.ref018], [@pone.0153459.ref019]\], few studies have examined the relationship between PLR and sensitivity to chemotherapy. We conducted a study on whether PLR could serve as a predictor of the therapeutic effects of NAC.

Materials and Methods {#sec006}
=====================

Patient Background {#sec007}
------------------

As described in detail previously \[[@pone.0153459.ref031]\], a total of 177 patients with resectable, early-stage breast cancer diagnosed as stage IIA (T1, N1, M0 or T2, N0, M0), IIB (T2, N1, M0 or T3, N0, M0) or IIIA (T1-2, N2, M0 or T3, N1-2, M0) were treated with NAC between 2007 and 2013. [Our previous report also used the same patient population as the present study, but it was a study of the significance of androgen receptor expression]{.ul} \[[@pone.0153459.ref031]\]. Tumor stage and T and N factors were stratified based on the TNM Classification of Malignant Tumors, Union for International Cancer Control (UICC) Seventh Edition \[[@pone.0153459.ref032]\]. Breast cancer was confirmed histologically using core needle biopsies and staged with systemic imaging studies using computed tomography (CT), ultrasonography (US) and bone scintigraphy. Breast cancer was classified into subtypes according to the immunohistochemical expression of the estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (HER2), and Ki67. Cutoffs for ER and PR positivity were both \>0% positive tumor cells with nuclear staining. Tumors with 3+ HER2 on immunohistochemical staining were considered to show HER2 overexpression; tumors with 2+ HER2 were further analyzed using fluorescence *in situ* hybridization; and those with HER2/CEP17 ≥2.0 were also considered to exhibit HER2 overexpression. A Ki67-labeling index ≥14% tumor cells with nuclear staining was determined to be positive.

All patients received a standardized protocol of NAC consisting of four courses of FEC100 (500 mg/m^2^ fluorouracil, 100 mg/m^2^ epirubicin and 500 mg/m^2^ cyclophosphamide) every 3 weeks, followed by 12 courses of 80 mg/m^2^ paclitaxel administered weekly \[[@pone.0153459.ref033], [@pone.0153459.ref034]\]. Forty-five patients had HER2-positive breast cancer and were additionally administered weekly (2 mg/kg) or tri-weekly (6 mg/kg) trastuzumab during paclitaxel treatment \[[@pone.0153459.ref035]\]. All patients underwent chemotherapy as outpatients.

Therapeutic anti-tumor effects were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria \[[@pone.0153459.ref036]\]. Pathologic complete response (pCR) was defined as the complete disappearance of the invasive components of the lesion with or without intraductal components, including in the lymph nodes. Patients underwent mastectomy or breast-conserving surgery after NAC. All patients who underwent breast-conserving surgery were administered postoperative radiotherapy to the remnant breast. The postoperative adjuvant therapy performed endocrine therapy and/or anti-HER2 treatment depending on every case.

Overall survival (OS) time was defined as the period from the initiation of NAC to the time of death from any cause. Disease-free survival (DFS) was defined as freedom from all local, loco-regional and distant recurrences. All patients were followed up with a physical examination every 3 months, US every 6 months, and CT and bone scintigraphy annually. The median follow-up period for the assessment of OS was 3.4 years (range, 0.6--6.0 years) and for DFS, it was 3.1 years (range, 0.1--6.0 years).

Ethics Statement {#sec008}
----------------

This research conformed to the provisions of the 1995 Declaration of Helsinki. All patients were informed of the investigational nature of this study and provided their written informed consent. The Ethics Committee of Osaka City University approved the study protocol (\#926).

Blood Sample Analysis {#sec009}
---------------------

Peripheral blood was obtained at the time of diagnosis, before NAC. The number of blood cells was determined using a hemocytometer. Percentages of different cell types were determined using a Coulter LH 750 Hematology Analyzer (Beckman Coulter, Brea, CA, USA). PLR was calculated from the preoperative blood sample by dividing the absolute platelet count by the absolute lymphocyte count. On the basis of previous studies, a PLR value of 150.0 was used as the cutoff value to discriminate between high-PLR (≥150.0) and low-PLR (\<150.0) \[[@pone.0153459.ref037]\].

Statistical Analysis {#sec010}
--------------------

Statistical analysis was performed using the SPSS version 19.0 statistical software package (IBM, Armonk, NY, USA). We examined associations between PLR and clinicopathologic variables sing the chi-squared test (or Fisher's exact test when necessary). The association with survival was analysed using the Kaplan--Meier plot and log-rank test. The Cox proportional hazards model was used to compute univariable and multivariable hazard ratios (HR) for the study parameters with 95% confidence intervals (c.i.), and used in a backward stepwise method for variable selection in multivariate analysis. In all of the tests, a *p*-value of less than 0.05 was considered statistically significant. Cut-off values for different biomarkers included in this study were chosen before statistical analysis.

Results {#sec011}
=======

In this study, NAC was administered to 177 patients with early-stage breast cancer. The therapeutic effect was pCR in 67 patients (37.9%) and non-pCR in 110 patients (62.1%) ([Table 1](#pone.0153459.t001){ref-type="table"}). PLR was determined in every sample and ranged from 40.5--463.0 (mean, 148.6; median, 135.2; standard deviation, 66.6). The high-PLR group comprised 67 patients (37.9%) and the low-PLR group comprised 110 patients (62.1%). Patients who received NAC were sorted into high- and low-PLR groups and the clinicopathological characteristics of each group were examined. The low-PLR group had significantly more patients \> 56 years old (the median value of age) (p = 0.001) and postmenopausal women (p = 0.001) than the high-PLR group. The low-PLR group also had a higher pCR rate (p = 0.019) ([Table 2](#pone.0153459.t002){ref-type="table"}). However, no correlation was seen with other clinicopathological factors, including subtype.

10.1371/journal.pone.0153459.t001

###### Clinical response rate and pathological response rate to neoadjuvant chemotherapy.

![](pone.0153459.t001){#pone.0153459.t001g}

  pathological response                         all breast cancers (n = 177)   TNBC (n = 61, 34.5%)   HER2BC (n = 36, 20.3%)   HRBC (n = 80, 45.2%)
  --------------------------------------------- ------------------------------ ---------------------- ------------------------ ----------------------
  pCR: pathological complete response           67 (37.9%)                     28 (45.9%)             18 (50.0%)               21 (26.3%)
  non-pCR: non-pathological complete response                                                                                  
  PR: partial response                          84 (47.5%)                     21 (34.4%)             15 (41.7%)               48 (60.0%)
  SD: stable disease                            19 (10.7%)                     8 (13.1%)              3 (8.3%)                 8 (10.0%)
  PD: progressive disease                       7 (3.9%)                       4 (6.6%)               0 (0.0%)                 3 (3.7%)
  RR (CR+PR): response rate                     151 (85.3%)                    49 (80.3%)             33 (91.7%)               69 (86.3%)

TNBC, triple-negative breast cancer. HER2BC, human epidermal growth factor receptor 2-enriched breast cancer. HRBC, hormone receptor-positive breast cancer. CR, complete response. PR, partial response. SD, stable disease. PD, progressive disease.

10.1371/journal.pone.0153459.t002

###### Correlation between clinicopathological features and platelet--lymphocyte ratio in 177 all breast cancers.

![](pone.0153459.t002){#pone.0153459.t002g}

  Parameters              PLR (n = 177)   p value      
  ----------------------- --------------- ------------ -------
  Age at operation                                     
  ≤56                     44 (65.7%)      43 (39.1%)   
  \>56                    23 (34.3%)      67 (60.9%)   0.001
  Menopause                                            
  Negative                38 (56.7%)      34 (30.9%)   
  Positive                29 (43.3%)      76 (69.1%)   0.001
  Tumor size                                           
  ≤2 cm                   8 (11.9%)       16 (14.5%)   
  \>2 cm                  59 (88.1%)      94 (85.5%)   0.623
  Lymph node status                                    
  Negative                17 (25.4%)      24 (21.8%)   
  Positive                50 (74.6%)      86 (78.2%)   0.587
  Nuclear grade                                        
  1, 2                    53 (79.1%)      84 (76.4%)   
  3                       14 (20.9%)      26 (23.6%)   0.672
  Ki67                                                 
  ≤14%                    32 (47.8%)      42 (38.2%)   
  \>14%                   35 (52.2%)      68 (61.8%)   0.210
  Intrinsic subtype                                    
  TNBC                    25 (37.3%)      36 (32.7%)   
  non-TNBC                42 (62.7%)      74 (67.3%)   0.533
  Pathological response                                
  pCR                     18 (26.9%)      49 (44.5%)   
  non-pCR                 49 (73.1%)      61 (55.5%)   0.019

PLR, platelet--lymphocyte ratio. TNBC, triple-negative breast cancer. pCR, pathologic complete response.

On examining the correlation with prognosis, the low-PLR group was found to have significantly longer DFS (p = 0.004, log-rank) ([Fig 1A](#pone.0153459.g001){ref-type="fig"}) and OS (p = 0.032, log-rank) ([Fig 1B](#pone.0153459.g001){ref-type="fig"}) than the high PLR group. Univariate analysis revealed that lymph node metastasis (*p* = 0.049, hazard ratio = 4.23) and a high PLR (*p* = 0.006, hazard ratio = 2.77) were unfavorable prognostic factors ([Fig 2](#pone.0153459.g002){ref-type="fig"}). Moreover, multivariate analysis also revealed that lymph node metastasis (*p* = 0.043, hazard ratio = 4.40) and a high PLR (*p* = 0.005, hazard ratio = 2.84) were independent, unfavorable prognostic factors ([Table 3](#pone.0153459.t003){ref-type="table"}).

10.1371/journal.pone.0153459.t003

###### Univariable and multivariable analysis with respect to disease-free survival in breast cancer.

![](pone.0153459.t003){#pone.0153459.t003g}

                          Univariable analysis   Multivariable analysis                                
  ----------------------- ---------------------- ------------------------ ------- ------ ------------- -------
  Tumor size (cm)                                                                                      
   ≤2 vs \>2              1.06                   0.37--3.05               0.911                        
  Menopause                                                                                            
   Negative vs Positive   0.84                   0.41--1.73               0.637                        
  Hormone receptor                                                                                     
   Negative vs Positive   1.05                   0.51--2.16               0.886                        
  HER2                                                                                                 
   Negative vs Positive   0.695                  0.27--1.82               0.459                        
  Nuclear grade                                                                                        
   1--2 vs 3              1.03                   0.44--2.39               0.954                        
  Ki67 (%)                                                                                             
   ≤14 vs \>14            0.65                   0.32--1.33               0.238                        
  Pathological response                                                                                
   pCR vs non-pCR         0.61                   0.28--1.34               0.217   0.75   0.34--1.66    0.475
  Lymph node status                                                                                    
   Negative vs Positive   4.23                   1.01--17.78              0.049   4.40   1.05--18.48   0.043
  PLR                                                                                                  
   High vs Low            2.77                   1.33--5.76               0.006   2.84   1.37--5.91    0.005

c.i., confidence interval. HER2, human epidermal growth factor receptor 2. pCR, pathological complete response. PLR, platelet--lymphocyte ratio.

![Examination of the correlation with prognosis.\
The low-PLR group was found to have significantly longer disease-free survival (p = 0.004, log-rank) (A) and overall survival (p = 0.032, log-rank) (B) than the high PLR group.](pone.0153459.g001){#pone.0153459.g001}

![Forest plots.\
Univariate analysis revealed that absence of lymph node metastasis and a low PLR were good prognostic factors.](pone.0153459.g002){#pone.0153459.g002}

Discussion {#sec012}
==========

In the past it was believed that cancer cells could autonomously proliferate and survive because of a variety of genetic abnormalities, but recently it has become clear that the peripheral environment (tumor microenvironment) greatly affects cancer cells and contributes to the formation of characteristics particular to cancer. Therefore, monitoring the host\'s tumor microenvironment is believed to play a key role in predicting therapeutic efficacy and prognosis. Systematic inflammatory indicators, such as NLR or PLR, have been reported as monitoring the host\'s tumor microenvironment. \[[@pone.0153459.ref014],[@pone.0153459.ref037],[@pone.0153459.ref038]\].

The cell proliferation process, particularly autonomous proliferation, is important to elucidate the mechanisms of carcinogenesis, as growth factors and their receptors are closely related to cancer genes \[[@pone.0153459.ref024]\]. Platelet-derived growth factors include PDGF \[[@pone.0153459.ref021], [@pone.0153459.ref022]\], TGF-β \[[@pone.0153459.ref026], [@pone.0153459.ref027]\] and PD-ECGF \[[@pone.0153459.ref026], [@pone.0153459.ref029], [@pone.0153459.ref038]\], and are involved in the repair and regeneration of tissue. PDGF has a similar structure to the protein that makes up the *sis* cancer gene, and the tyrosine kinase structure seen in PDGF receptors is found in some cancer genes. Moreover, administration of PDGF induces cancer genes such as *myc* and *fos*, which are present in the cell nucleus. This suggests that abnormalities that occur in the growth factor activation process are linked to the canceration of cells \[[@pone.0153459.ref025]\]. TGF-β works to inhibit cancer through cytostatic activity in the early stages of carcinogenesis; however, it conversely works to promote cancer in the later stages as the cancer develops \[[@pone.0153459.ref026]\].

Platelet-derived growth factors are frequently created in large quantities by cancer cells and have an effect on the histology of cancer \[[@pone.0153459.ref025], [@pone.0153459.ref026], [@pone.0153459.ref038]\]. They have been found to contribute to metastasis, invasion and growth of the primary tumor. Peripheral blood platelet count may thus be an indicator of tumor activity. Meanwhile, lymphocytes are responsible for the immune response to tumor growth, and peripheral blood lymphocyte count is thought to be an indicator of tumor suppression. This would suggest that patients in a low-PLR group, with a low platelet count and high lymphocyte count, exhibit high antitumor activity, which would be correlated with a good prognosis and chemotherapy sensitivity. The patients in the low-PLR group in the present study showed a correlation between PLR and the pCR rate, which was an independent, good prognostic factor.

The mechanism whereby PLR and chemotherapy sensitivity are correlated is thought to occur as follows. Platelets are cells that contain the largest quantity of growth factors, and platelet count is an indicator of cancer activity. A low platelet count suggests cancer with low activity. Chemotherapy promotes myelosuppression and lowers the platelet count. Furthermore, chemotherapy increases lymphocyte count by activating the immune response. This is thought to relatively lower the PLR and enhance the antitumor effects.

We have reported on the usefulness of NLR as a predictor of the effect of NAC in triple-negative breast cancer \[[@pone.0153459.ref006], [@pone.0153459.ref007]\]; however, no correlation was seen between PLR and NAC sensitivity with subtype. NLR is useful as an effective predictive marker in a high lymphocyte activity subtype such as triple-negative breast cancer. On the other hand, PLR was not useful as an effect predictive marker according to subtype, because of growth factor participation. The indication criteria of NAC should be decided by progress degree and intrinsic subtype. However, the high-PLR group that an effect cannot expect so much may become an adjuvant biomarker.

Conclusions {#sec013}
===========

In NAC treatment of breast cancer, a low PLR indicated high chemotherapy sensitivity, suggesting that PLR could serve as a predictive marker of the therapeutic effect of NAC.
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